@entity136 and Infusional @entity1487 in Advanced XXXX : A Clinical Benefit Response-Oriented Phase II Study.

@entity1 @entity3123 @entity788 @entity137 @entity882 @entity1398 @entity158 @entity136 @entity1487
PURPOSE: @entity136 and @entity1487 ( @entity1487 ) are two compounds with reproducible activity against advanced @entity3123 . To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study was performed. MATERIALS AND METHODS: Twenty @entity1 (male: female 15: 5, median age: 60.5 years), with histologically verified locally advanced or metastatic @entity3123 , were enrolled between April 2000 and March 2002. @entity136 was administered by intravenous injection at the doses of 1, 000 mg/m2 on days 1, 8 and 15, and @entity1487 800 mg/m2/day, was given by continuous intravenous infusion on days 1~5. The treatment was repeated every 4 weeks. The clinical benefit response (CBR) was a composite of the @entity158 , Karnofsky performance status and body weight change measurement. RESULTS: Nineteen of the twenty @entity1 were assessable for response. The median follow-up duration was 4.6 months (0.4~15.2 months). Five @entity1 achieved a partial response and eight a stable disease. The overall response rate was 25.0%. The CBR was assessable in 12 @entity1 . The overall CBR was 41.7% (5/12). The median survival of all the @entity1 was 8.0 months. Grade 3~4 @entity137 included @entity1398 (9.3%) and @entity882 (5.3%). CONCLUSION: This study suggested that @entity136 , combined with infusional @entity1487 , was well tolerated, and produced modest antitumor activity and symptomatic relief in advanced @entity788 @entity1 .
